Trial Profile
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Sirolimus (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 11 Mar 2024 Planned End Date changed from 1 Dec 2023 to 19 Apr 2028.
- 11 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 19 Apr 2028.
- 07 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Dec 2023.